

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CTLMIM.21CP1CAPPLICATION NO.
10/026,066INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Simard et al.FILING DATE
December 7, 2001GROUP
1644

RECEIVED

DEC 10 2002

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---------------------|-----|-----------------|----------|-------------------|-------|----------|---------------------------------|
| <i>AV</i> | 1. | 4,439,199 | 03/27/84 | Amkraut et al. | | | |
| | 2. | 4,937,190 | 06/28/90 | Palmenberg et al. | | | |
| | 3. | 5,093,242 | 03/03/92 | Bachmair et al. | | | |
| | 4. | 5,132,213 | 06/21/92 | Bachmair et al. | | | |
| | 5. | 5,168,062 | 12/01/92 | Stinski | | | |
| | 6. | 5,258,294 | 11/02/93 | Boyle, et al. | | | |
| | 7. | 5,385,839 | 01/31/95 | Stinski | | | |
| | 8. | 5,478,556 | 12/26/95 | Elliot et al. | | | |
| | 9. | 5,496,721 | 03/05/96 | Bachmair et al. | | | |
| | 10. | 5,580,859 | 12/03/96 | Felgner et al. | | | |
| | 11. | 5,589,466 | 12/31/96 | Felgner et al. | | | |
| | 12. | 5,646,017 | 07/08/97 | Bachmair et al. | | | |
| | 13. | 5,679,647 | 10/21/97 | Carson et al. | | | |
| | 14. | 5,698,396 | 12/16/97 | Pfreundschuh | | | |
| | 15. | 5,733,548 | 03/31/98 | Restifo et al. | | | |
| | 16. | 5,744,316 | 04/28/98 | Lethe et al. | | | |
| | 17. | 5,747,269 | 05/05/98 | Rammensee et al. | | | |
| | 18. | 5,844,075 | 12/01/98 | Kawakami, et al. | | | |
| | 19. | 5,846,540 | 12/08/98 | Restifo et al. | | | |
| | 20. | 5,847,097 | 12/08/98 | Bachmair et al. | | | |
| | 21. | 5,856,187 | 01/05/99 | Restifo et al. | | | |
| | 22. | 5,925,565 | 07/20/99 | Berlioz et al. | | | |
| | 23. | 5,962,428 | 10/05/99 | Carrano et al. | | | |
| | 24. | 5,989,565 | 11/23/99 | Storkus et al. | | | |
| | 25. | 5,993,828 | 11/30/99 | Morton | | | |
| | 26. | 5,994,523 | 11/30/99 | Kawakami et al. | | | |
| | 27. | 6,008,200 | 12/28/99 | Krieg | | | |

EXAMINER

DATE CONSIDERED

6/10/04

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | | | | | |
|-------------------------------------------------------------------------------------------|-----|------------------------------------------------------------|----------|-----------------------------------|-------|-------------------------------|---------------------------------|
| FORM PTO-1449 | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. CTLIMM.21CP1C | | APPLICATION NO. 10/026,066 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | | | | APPLICANT Simard et al. | | | |
| | | | | FILING DATE December 7, 2001 | | GROUP 1644 | |
| RECEIVED JAN 24 2003 TECH CENTER 1600/2900 | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
| R | 28. | 6,037,135 | 03/14/00 | Kubo et al. | / | / | |
| I | 29. | 6,060,273 | 05/09/00 | Dirks et al. | / | / | |
| I | 30. | 6,287,569 | 09/11/01 | Kipps, et al. | / | / | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----|-----------------|----------|---------|-------|----------|-------------|----|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | YES | NO |
| R | 31. | 74899 | 08/13/97 | Ireland | / | / | | |
| I | 32. | 2,147,863 | 05/26/94 | Canada | / | / | | |
| I | 33. | DE 44 23 392 A1 | 01/11/96 | Germany | / | / | | |
| I | 34. | WO 92/01072 | 12/30/92 | PCT | / | / | | |
| I | 35. | EP 1 118 860 A1 | 07/25/01 | EPO | / | / | | |
| I | 36. | WO 92/21033 | 11/26/92 | PCT | / | / | | |
| I | 37. | EP 93/03175 | 04/08/95 | PCT | / | / | | |
| I | 38. | WO 96/01429 | 01/18/96 | PCT | / | / | | |
| I | 39. | WO 96/40209 | 12/19/96 | PCT | / | / | | |
| I | 40. | WO 97/34613 | 09/25/97 | PCT | / | / | | |
| I | 41. | WO 97/41440 | 11/08/97 | PCT | / | / | | |
| I | 42. | WO 98/13489 | 04/02/98 | PCT | / | / | | |
| I | 43. | WO 98/14464 | 04/09/98 | PCT | / | / | | |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | |
|---------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R | 44. | Aki et al., "Interferon- γ Induces Different Subunit Organizations and Functional Diversity of Proteasomes," <i>J. Biochem.</i> , 115: 257-260 (1994) |
| I | 45. | Altuvia et al., "A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets," <i>Human Immunology</i> , 58: 1-11 (1997) |
| I | 46. | Arnold et al., "Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules," <i>Nature</i> , 360: 171-174 (1992) |
| I | 47. | Ayyoub, et al., "Lack of tumor recognition by hTERT peptide 540-548-specific CD8 ⁺ T cells from melanoma patients reveals inefficient antigen processing," <i>Eur. J. Immunol.</i> , 31:2642-2651 (2001) |
| I | 48. | Bachman et al., "In vitro vs. in vivo assays for the assessment of T-and B cell function," <i>Curr. Opin. Immunol.</i> , 6: 320-326 (1994) |

| | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-----------------|---------|
| EXAMINER | <i>D. R. [Signature]</i> | DATE CONSIDERED | 6/10/04 |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | | | |

| | | | |
|-------------------------------------------------------------------------------------------|------------------------------------------------------------|-----------------------------------|-------------------------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. CTLIMM.21CP1C | APPLICATION NO. 10/026,066 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | | APPLICANT Simard et al. | DEC 10 2002 |
| | | FILING DATE December 7, 2001 | GROUP 1644 |



RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>av</i> | 49. Bettinotti et al., "Stringent Allele/Epitope Requirements for MART-1/Melan A Immunodominance: Implications for Peptide-Based Immunotherapy," <i>J. Immunol.</i> , 161: 877-889 (1998) |
| | 50. Boes et al., "Interferon γ Stimulation Modulates the Proteolytic Activity and Cleavage Site Preference of 20S Mouse Proteasomes," <i>J. Exp. Med.</i> , 179: 901-909 (1994) |
| | 51. Brown et al., "Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes," <i>Nature</i> , 353: 355-357 (1991) |
| | 52. Butterfield et al., "Generation of Melanoma-Specific Cytotoxic T Lymphocytes by Dendritic Cells Transduced with a MART-1 Adenovirus," <i>J. Immunol.</i> , 161: 5607-5613 (1998) |
| | 53. Chattergoon, et al., "Genetic Immunization: a new era in vaccines and immune therapeutics," <i>FASEB J.</i> , 11:753-763 (1997) |
| | 54. Chaux et al., "Identification of Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by In Vitro Stimulation with Dendritic Cells Transduced with MAGE-A1," <i>The Journal of Immunology</i> , 163: 2928-2936 (1999) |
| | 55. Davis, H. L., "Plasmid DNA expression systems for the purpose of immunization," <i>Current Opinion in Immunology</i> , 8: 635-640 (1997) |
| | 56. Dean et al., "Sequence requirements for plasmid nuclear import," <i>Experimental Cell Research</i> , 253: 713-722 (1999) |
| | 57. DeGroot et al., "An Interactive Web Site Providing Major Histocompatibility Ligand Predictions: Application to HIV Research," <i>Aids Res. and Human Retrov.</i> , 13: 529-531 (1997) |
| | 58. Dick et al., "Coordinated Dual Cleavages Induced by the Proteasome Regulator PA28 Lead to Dominant MHC Ligands," <i>Cell</i> , 86: 253-262 (1996) |
| | 59. Dick, et al., "Proteolytic Processing of Ovalbumin and β -galactosidase by the Proteasome to Yield Antigenic Peptides," <i>J. of Immunology</i> , 152:3884-3894 (1994) |
| | 60. Driscoll et al., "MHC-linked LMP gene products specifically alter peptidase activities of the proteasome," <i>Nature</i> , 365: 262-264 (1993) |
| | 61. Durrant, L.G., "Cancer vaccines," <i>Anti-cancer drugs</i> , 8: 727-733 (1997) |
| | 62. Farrar et al., "The molecular cell biology of interferon- γ and its receptor," <i>Annu. Rev. Immunol.</i> , 11: 571-611 (1993) |
| | 63. Fietta et al., "Theiler's virus infection of 129Sv mice that lack the interferon α/β or interferon γ receptors," <i>J. Exp. Med.</i> , 181: 2069-2076 (1995) |
| | 64. Gaczynska et al., " γ -Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes," <i>Nature</i> , 365: 264-267 (1993) |
| | 65. Gale et al., "Evidence that hepatitis C Virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein," <i>Virology</i> , 230: 217-227 (1997) |
| | 66. Gileadi et al., "Generation of an Immunodominant CTL Epitope is Affected by Proteasome Subunit Composition and Stability of the Antigenic Protein," <i>Am. Assoc. of Immunol.</i> , 163: 6045-6052 (1999) |
| | 67. Glynnne et al., "A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC," <i>Nature</i> , 353: 357-360 (1991) |
| | 68. Groettrup et al., "A role for the proteasome regulator PA28a in antigen presentation," <i>Nature</i> , 381: 166-168 (1996) |
| | 69. Gulukota et al., "Two complementary methods for predicting peptides binding major histocompatibility complex molecules," <i>J. Mol. Biol.</i> , 267: 1258-1267 (1997) |
| | 70. Gurunathan et al., "DNA vaccines: a key for inducing long-term cellular immunity," <i>Current Opinion in Immunology</i> , 12: 442-447 (2000) |
| | 71. Heim et al., "Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway," <i>Journal of Virology</i> , 73: 8469-8475 (1999) |
| | 72. Huang et al., "Immune response in mice that lack the interferon- γ receptor," <i>Science</i> , 259: 1742-1745 (1993) |
| | 73. International Search Report from co-pending Application No. PCT/US01/13806 |
| | 74. Jager et al., "Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo," <i>Int. J. Cancer</i> , 67: 54-62 (1996) |
| | 75. Jager et al., "Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding Peptide Epitopes," <i>J. Exp. Med.</i> , 187: 265-270 (1998) |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| EXAMINER <i>OT. R. [Signature]</i> | DATE CONSIDERED <i>6/10/04</i> |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |

| | | | |
|-------------------------------------------------------------------------------------------|------------------------------------------------------------|-----------------------------------|-------------------------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. CTLIMM.21CP1C | APPLICATION NO. 10/026,066 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | | APPLICANT Simard et al. | DEC 10 2002 |
| | | FILING DATE December 7, 2001 | GROUP 1644 |



RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RV | 76. Kang et al., "Induction of Melanoma Reactive T Cells by Stimulator Cells Expressing Melanoma Epitope-Major Histocompatibility Complex Class I Fusion Proteins," <i>Cancer Res.</i> , 57: 202-205 (1997) |
| | 77. Kawakami et al., "The Use of Melanosomal Proteins in the Immunotherapy of Melanoma," <i>J. Immunother.</i> , 21:237-246 (1998) |
| | 78. Kelly et al., "Second proteasome-related gene in the human MHC class II region," <i>Nature</i> , 353:667-668 (1991) |
| | 79. Kittlesen et al., "Human Melanoma Patients Recognize an HLA-A1-Restricted CTL Epitope from Tyrosinase Containing Two Cysteine Residues: Implications for Tumor Vaccine Development," <i>J. Immunol.</i> , 160: 2099-2106 (1998) |
| | 80. Kundig et al., "Fibroblasts as efficient antigen-presenting cells in lymphoid organs," <i>Proc. Natl. Acad. Sci.</i> , 268:1343-1347 (1995) |
| | 81. Kundig et al., "On the role of antigen in maintaining cytotoxic T cell memory," <i>Proc. Natl. Acad. Sci. USA</i> , 93:9716-9723 (1996) |
| | 82. Larregina et al., "Direct Transfection and Activation of Human Cutaneous Dendritic Cells," <i>Gene Ther.</i> , 8:608-617 (2001) |
| | 83. Lee et al., "Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients," <i>Nature Medicine</i> , 5:677-685 (1999) |
| | 84. Leitner, et al., "DNA and RNA-based vaccines: principles, progress and prospects," <i>Vaccine</i> , 18:765-777 (2000) |
| | 85. Levy et al., "Using ubiquitin to follow the metabolic fate of a protein," <i>Proc. Natl. Acad. Sci USA</i> , 93: 4907-4912 (1996) |
| | 86. Linette et al., "In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8+ T Cells in Patients with Melanoma," <i>J. Immunol.</i> , 164: 3402-3412 (2000) |
| | 87. Loftus et al., "Peptides Derived from Self-Proteins as Partial Agonists and Antagonists of Human CD8+ T-cell Clones Reactive to Melanoma/Melanocyte Epitope MART1(27-35)," <i>Cancer Res.</i> , 11: 2433-2439 (1998) |
| | 88. Maksymowych et al., "Invasion by Salmonella typhimurium Induces Increased Expression of the LMP, MECL, and PA28 Proteasome Genes and Changes in the Peptide Repertoire of HLA-B27," <i>Infection and Immunity</i> , 66:4624-4632 (1998) |
| | 89. Martinez et al., "Homology of proteasome subunits to a major histocompatibility complex-linked LMP gene," <i>Nature</i> , 353:664-667 (1991) |
| | 90. Mateo et al., "An HLA-A2 polypeptide vaccine for melanoma immunotherapy," <i>The Journal of Immunology</i> , 163: 4058-4063 (1999) |
| | 91. McCluskie, et al., "Route and Method of Delivery of DNA Vaccine Influence Immune Response in Mice and Non-Human Primates," <i>Molecular Medicine</i> , 5:287-300 (1999) |
| | 92. Meister et al., "Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences," <i>Vaccine</i> , 13: 581-591 (1995) |
| | 93. Melief, C. J., <i>Cancerlit</i> , Database Accession No. 1998625858, "Towards T-cell immunotherapy of cancer," Meeting Abstract (1996) |
| | 94. Miconnet et al., "Amino acid identity and/or position determine the proteasomal cleavage of the HLA-A *0201-restricted peptide tumor antigen MAGE-3," <i>The American Society for Biochemistry and Molecular Biology, Inc.</i> , page 20 (2000) |
| | 95. Missale et al., "HLA-A31 and HLA-Aw68-restricted Cytotoxic T cell Responses to a Single Hepatitis B Virus Nucleocapsid Epitope during Acute Viral Hepatitis," <i>J. Exp. Med.</i> , 177: 751-762 (1993) |
| | 96. Momburg et al., "Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation," <i>Nature</i> , 360: 174-177 (1992) |
| | 97. Morel et al., "Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells," <i>Immunity</i> , 12: 107-117 (2000) |
| | 98. Moskopidhis et al., "Immunobiology of Cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus," <i>Journal of Virology</i> , 69: 7423-7429 (1995) |
| | 99. Murphy et al., "Higher-Dose and Less Frequent Dendritic Cell Infusions with PSMA Peptides in Hormone-Refractory Metastatic Prostate Cancer Patients," <i>The Prostate</i> , 43: 59-62 (2000) |
| | 100. Noppen et al., "Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2," <i>Int. J. Cancer</i> , 87: 241-246 (2000) |
| | 101. Nussbaum et al., "Cleavage motifs of the yeast 20S proteasome & subunits deduced from digest of enolase 1," <i>Proc. Natl. Acad. Sci USA</i> , 95: 12504-12509 (1998) |


| | |
|--------------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| <i>[Signature]</i> | 6/10/04 |

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|-------------------------------------------------------------------------------------------|------------------------------------------------------------|-----------------------------------|----------------------------------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. CTLIMM.21CP1C | APPLICATION NO. 10/028,066 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | | APPLICANT Simard et al. | RECEIVED DEC 10 2002 |
| | | FILING DATE December 7, 2001 | GROUP 1644 TECH CENTER 1600/2900 |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>m</i> | 102. Oehen et al., "Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen," <i>J. Exp. Med.</i> 176: 1273-1281 (1992) |
| | 103. Oldstone et al., "Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection," <i>Journal of Virology</i> , 69: 7423-7429 (1995) |
| | 104. Ortiz-Navarrete et al., "Subunit of the '20S proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex," <i>Nature</i> , 353: 662-664 (1991) |
| | 105. Pantaleo et al., "Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection," <i>Proc. Natl. Acad. Sci.</i> , 94: 9848-9853 (1997) |
| | 106. Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains," <i>Journal of Immunology</i> , 152: 163 (1994) |
| | 107. Perez-Diaz et al., "Generation of CD8+ and CD4+ T-cell Response to Dendritic Cells Genetically Engineered to Express the MART-1/Melan-A Gene," <i>Cancer Res.</i> , 58: 5305-5309 (1998) |
| | 108. Preckel et al., "Impaired Immunoproteasome Assembly and Immune Responses in PA28-I-Mice," <i>Science</i> , 286: 2162-2165 (1999) |
| | 109. Puccetti et al., "Use of skin test assay to determine tumor-specific CD8+ T cell reactivity," <i>Eur. J. Immunol.</i> 24: 1446-1452 (1994) |
| | 110. Rammensee et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> , 41: 178-228 (1995) |
| | 111. Rammensee et al., "Peptide motifs: amino acids in peptide-MHC interactions," <i>Landes Bioscience Austin Texas</i> , Chapter 4: 217-369 (1997) |
| | 112. Rammensee et al., "SYFPEITHI: Database for MHC ligands and peptide motifs," <i>Immunogenetics</i> , 50: 213-219 (1999) |
| | 113. Raz et al., "Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization," <i>Proc. Natl. Acad. Sci. USA</i> , 93: 5141-5145 (1996) |
| | 114. Reeves et al., "Retroviral Transduction of Human Dendritic Cells with a Tumor-Associated Antigen Gene," <i>Cancer Res.</i> , 56: 5672-5677 (1996) |
| | 115. Rehmann et al., "The Cytotoxic T Lymphocyte Response to Multiple Hepatitis B Virus Polymerase Epitopes During and After Acute Viral Hepatitis," <i>Journal of Exp. Medicine</i> , 181: 1047-1058 (1995) |
| | 116. Roberts et al., "Prediction of HIV Peptide Epitopes by a Novel Algorithm," <i>Aids Research and Human Retroviruses</i> , 12: 593-610 (1996) |
| | 117. Rock et al., "Degradation of cell proteins and the generation of MHC class I-presented peptides," <i>Annu. Rev. Immunol.</i> , 17: 739-779 (1999) |
| | 118. Roman et al., "Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants," <i>Nature Medicine</i> , 3: 849-854 (1997) |
| | 119. Rosmorduc et al., "Inhibition of interferon-inducible Mx protein expression by hepatitis B virus capsid protein," <i>Journal of General Virology</i> , 80: 1253-1262 (1999) |
| | 120. Ryan et al., "A model for nonstoichiometric, cotranslational protein scission in eukaryotic ribosomes," <i>Bioorganic Chemistry</i> , 27: 55-79 (1999) |
| | 121. Salmi et al., "Tumor endothelium selectively supports binding of IL-2 propagated tumor-infiltrating lymphocytes," <i>The Journal of Immunology</i> , 154: 6002-6012 (1995) |
| | 122. Sato et al., "Immunostimulatory DNA sequences necessary for effective intradermal gene immunization," <i>Science</i> , 273: 352-354 (1996) |
| | 123. Schirle et al., "Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens," <i>Journal of Immunological Methods</i> , 257: 1-16 (2001) |
| | 124. Schneider, et al., "Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1," <i>Int. J. Cancer</i> , 75(3):451-458 (1998) |
| | 125. Seipelt et al., "The structures of picornaviral proteinases," <i>Virus Research</i> , 62: 159-168 (1999) |
| | 126. Sewell et al., "IFN-γ Exposes a Cryptic Cytotoxic T Lymphocyte Epitope in HIV-1 Reverse Transcriptase," <i>J. Immunol.</i> , 162: 7075-7079 (1999) |
| | 127. Sijts et al., "Efficient Generation of a Hepatitis B Virus Cytotoxic T Lymphocyte Epitope Requires the Structural Features of Immunoproteasomes," <i>Journal of Exp. Medicine</i> , 191: 503-513 (2000) |
| | 128. Speiser et al., "Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy," <i>Journal Exp. Medicine</i> , 186: 645-653 (1997) |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| EXAMINER <i>OT. R. J. L. J.</i> | DATE CONSIDERED <i>6/10/04</i> |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |


| | | | |
|-------------------------------------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. CTLMM.21CP1C | APPLICATION NO. 10/026,066 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | |  | |
| | | RECEIVED DEC 10 2002 | |
| | | APPLICANT Simard et al. | GROUP 1644 |
| | | FILING DATE December 7, 2001 | TECH CENTER 1600/2900 |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | 129. Stauss et al., "Induction of Cytotoxic T Lymphocytes with Peptides In Vitro: Identification of Candidate T-cell Epitopes in Human Papilloma," <i>Proc. Natl. Acad. Sci.</i> , 89: 7671-7675 (1992) |
| | 130. Steinman et al., "The dendritic cell system and its role in immunogenicity," <i>Annual Review of Immunology</i> , 9: 271-296 (1991) |
| | 131. Stumliolo et al., "Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices," <i>Nature Biotechnology</i> , 17: 555-561 (1999) |
| | 132. Taylor et al., "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein," <i>Science</i> , 285: 107-110 (1999) |
| | 133. Thomson et al., "Minimal epitopes expressed in a recombinant polypeptide protein are processed and presented to CD8 ⁺ cytotoxic T cells: Implications for vaccine design," <i>Proc. Natl. Acad. Sci. USA</i> , 92: 5845-5849 (1995) |
| | 134. Tjoo et al., "Evaluation of Phase I/II Clinical Trials in Prostate Cancer with Dendritic Cells and PSMA Peptides," <i>The Prostate</i> , 36: 39-44 (1998) |
| | 135. Twu et al., "Transcription of the human beta interferon gene is inhibited by hepatitis B virus," <i>Journal of Virology</i> , 63: 3065-3071 (1989) |
| | 136. Valmori et al., "Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue," <i>J. Immunol.</i> , 164: 1125-1131 (2000) |
| | 137. Van den Eynde et al., "Differential Processing of Class-I-Restricted Epitopes by the Standard Proteasome and the Immunoproteasome," <i>Curr. Opinion in Immunol.</i> , 13: 147-153 (2001) |
| | 138. Van Kaer et al., "Altered Peptidase and Viral-Specific T Cell Response in LMP2 Mutant Mice," <i>Immunity</i> 1: 533-541 (1994) |
| | 139. Vitiello et al., "Comparison of Cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance," <i>Euro. Jr. Immunol.</i> , 27: 671-678 (1997) |
| | 140. Wang et al., "Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma," <i>Clin. Cancer Res.</i> , 10: 2756-2765 (1999) |
| | 141. Yang et al., "Proteasomes Are Regulated By Interferon γ : Implications For Antigen Processing," <i>Proc. Natl. Acad. Sci.</i> , 89: 4928-4932 (1992) |
| | 142. Yewdell, et al., "MHC-Encoded Proteasome Subunits LMP2 and LMP7 Are Not Required for Efficient Antigen Presentation," <i>J. Immunology</i> 1994, 152:1163-1170 (1994) |
| | 143. Young et al., "Dendritic Cells As Adjuvants For Class I Major Histocompatibility Complex-Restricted Antitumor Immunity," <i>J. Exp. Med.</i> , 183: 7-11 (1996) |
| | 144. Zajac et al., "Enhanced Generation of Cytotoxic T Lymphocytes Using Recombinant Vaccinia Virus Expressing Human Tumor-Associated Antigens and B7 Costimulatory Molecules," <i>Cancer Res.</i> , 58: 4567-4571 (1998) |
| | 145. Zajac et al., "Generation of Tumoricidal Cytotoxic T Lymphocytes from Healthy Donors after In Vitro Stimulation with a Replication-Incompetent Vaccinia Virus Encoding MART-1/Melan-A 27-35 Epitope," <i>Int. J. Cancer</i> , 71: 491-496 (1997) |
| | 146. Zhai et al., "Antigen-Specific Tumor Vaccines. Development and Characterization of Recombinant Adenoviruses Encoding MART1 or gp100 for Cancer Therapy," <i>J. Immunol.</i> , 156: 700-710 (1996) |
| | 147. Zipkin, I., "Cancer vaccines," <i>Bio Century</i> , 6: A1-A6 (1998) |
| | 148. NCBI Blast Accession Number NP_005502 |

S:\DOCS\MTMMTM-3114.DOC\083102

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
MANNK.021CP1CAPPLICATION NO.
10/026,066INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Simard et al.FILING DATE
December 7, 2001GROUP
1644

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---------------------|-----------------|------|------|-------|----------|---------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---------------------|-----------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

| | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | International Search Report to International Application No. PCT/US02/36098 Date of Mailing of International Search Report: 15 January 2004 |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |


S:\DOCS\SRG\SRG-2537.DOC\021204Vvo

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | | |
|-------------------------------------------------------------------------------------------|------------------------------------------------------------|----------------------------------------------------------------|-------------------------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. MANNK.021CP1C (Formerly CTLIMM.021CP1C) | APPLICATION NO. 10/028,066 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | | APPLICANT Simard, et al.. | |
| | | FILING DATE December 7, 2001 | GROUP 1644 |



| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|---|-----------------|---------|-----------|-------|----------|---------------------------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
| <i>m</i> | 1 | 4,683,199 A | 07/1987 | Palladino | — | — | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|---|---------------------------|--------------------|------------------------------------------------------------------------------------|-------|----------|-------------|----|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | YES | NO |
| | 2 | WO 97/41440 A1 | 11/1997 | W.I.P.O. (*previously submitted in an Information Disclosure Statement) | | | | |
| <i>m</i> | 3 | WO 01/090197 A1 | 11/2001 | W.I.P.O. | — | — | | |
| <i>l</i> | 4 | WO 99/24596 A1 | 05/1999 | W.I.P.O. | — | — | | |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | |
|---------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | 5 | Van DEN EYNDE, et al. "Differential processing of class-I restricted epitopes by the standard proteasome and the immunoproteasome," Current Opinion in Immunology, Vol. 13, pp. 147-153 (2001). (*previously submitted in an Information Disclosure Statement) |
| <i>m</i> | 6 | International Search Report re International Application No. PCT/US03/26231 Date of Mailing of International Search Report: 02 December 2003 |
| <i>m</i> | 7 | International Search Report re International Application No. PCT/US02/35582 Date of Mailing of International Search Report: 14 November 2003 |

S:\DOCS\MTMMTM-5622.DOC
012004.dmr

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| EXAMINER <i>J. R. [Signature]</i> | DATE CONSIDERED <i>6/10/04</i> |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |